These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 37051238)
21. Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework. Feng Q; Huang Z; Song L; Wang L; Lu H; Wu L Eur J Med Res; 2023 Aug; 28(1):306. PubMed ID: 37649103 [TBL] [Abstract][Full Text] [Related]
22. Identification and validation of a fatty acid metabolism-related lncRNA signature as a predictor for prognosis and immunotherapy in patients with liver cancer. Chen E; Yi J; Jiang J; Zou Z; Mo Y; Ren Q; Lin Z; Lu Y; Zhang J; Liu J BMC Cancer; 2022 Oct; 22(1):1037. PubMed ID: 36195833 [TBL] [Abstract][Full Text] [Related]
23. Characterization of immune features and immunotherapy response in subtypes of hepatocellular carcinoma based on mitophagy. Wang Y; Peng B; Ning C; He S; Yang H; Mao Y; Sun L Front Immunol; 2022; 13():966167. PubMed ID: 36304466 [TBL] [Abstract][Full Text] [Related]
24. A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma. Sun J; Xi L; Zhang D; Gao F; Wang L; Yang G Sci Rep; 2023 Oct; 13(1):18709. PubMed ID: 37907783 [TBL] [Abstract][Full Text] [Related]
25. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma. Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566 [TBL] [Abstract][Full Text] [Related]
26. Identification of Ferroptosis-related molecular model and immune subtypes of hepatocellular carcinoma for individual therapy. Long S; Chen Y; Wang Y; Yao Y; Xiao S; Fu K Cancer Med; 2023 Jan; 12(2):2134-2147. PubMed ID: 35841206 [TBL] [Abstract][Full Text] [Related]
27. Identification of hepatocellular carcinoma prognostic markers based on 10-immune gene signature. Zhao K; Xu L; Li F; Ao J; Jiang G; Shi R; Chen F; Luo Q Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32789471 [TBL] [Abstract][Full Text] [Related]
28. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma. Zhang G; Zhang K; Zhao Y; Yang Q; Lv X BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751 [TBL] [Abstract][Full Text] [Related]
29. Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. Wang T; Dai L; Shen S; Yang Y; Yang M; Yang X; Qiu Y; Wang W Front Immunol; 2022; 13():843408. PubMed ID: 35693827 [TBL] [Abstract][Full Text] [Related]
30. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment. Gao B; Wang Y; Lu S Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232 [TBL] [Abstract][Full Text] [Related]
31. The liquid-liquid phase separation signature predicts the prognosis and immunotherapy response in hepatocellular carcinoma. Wang Z; Wang G; Zhao P; Sun P J Cell Mol Med; 2024 Jul; 28(14):e18446. PubMed ID: 39072983 [TBL] [Abstract][Full Text] [Related]
32. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on NK cell marker genes to predict prognosis and immunotherapy response in hepatocellular carcinoma. Yang D; Zhao F; Su Y; Zhou Y; Shen J; Yu B; Zhao K; Ding Y J Cancer Res Clin Oncol; 2023 Sep; 149(12):10609-10621. PubMed ID: 37296316 [TBL] [Abstract][Full Text] [Related]
33. Identification of secretory pathway-related genes based on Random Forest algorithm to predict the prognosis and immunotherapy response of hepatocellular carcinoma. Wang Z; Shi P; Huang P; Xu C; He Y; Lei W J Gene Med; 2024 Jan; 26(1):e3593. PubMed ID: 37730948 [TBL] [Abstract][Full Text] [Related]
34. A stemness-based eleven-gene signature correlates with the clinical outcome of hepatocellular carcinoma. Hong L; Zhou Y; Xie X; Wu W; Shi C; Lin H; Shi Z BMC Cancer; 2021 Jun; 21(1):716. PubMed ID: 34147074 [TBL] [Abstract][Full Text] [Related]
35. Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. Li L; Xie R; Lu G Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 34027555 [TBL] [Abstract][Full Text] [Related]
36. Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma. Tang Y; Guo C; Yang Z; Wang Y; Zhang Y; Wang D Front Immunol; 2022; 13():862527. PubMed ID: 35493471 [TBL] [Abstract][Full Text] [Related]
37. Identification of copper metabolism and cuproptosis-related subtypes for predicting prognosis tumor microenvironment and drug candidates in hepatocellular carcinoma. Liu X; Sun B; Yao Y; Lai L; Wang X; Xiong J; Zhang X; Jiang J Front Immunol; 2022; 13():996308. PubMed ID: 36275743 [TBL] [Abstract][Full Text] [Related]
38. A Four Amino Acid Metabolism-Associated Genes (AMGs) Signature for Predicting Overall Survival Outcomes and Immunotherapeutic Efficacy in Hepatocellular Carcinoma. Liao LS; Xiao ZJ; Wang JL; Liu TJ; Huang FD; Zhong YP; Zhang X; Chen KH; Du RL; Dong MY Biochem Genet; 2024 Jun; 62(3):1577-1602. PubMed ID: 37658254 [TBL] [Abstract][Full Text] [Related]
39. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma. Chen X; Hu G; Xiong L; Xu Q Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162 [No Abstract] [Full Text] [Related]
40. Mitochondrial-Related Transcriptome Feature Correlates with Prognosis, Vascular Invasion, Tumor Microenvironment, and Treatment Response in Hepatocellular Carcinoma. Wang Y; Song F; Zhang X; Yang C Oxid Med Cell Longev; 2022; 2022():1592905. PubMed ID: 35535359 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]